NASDAQ:QNTM Quantum Biopharma Q1 2025 Earnings Report $3.44 -0.07 (-1.99%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$3.41 -0.03 (-0.76%) As of 07/6/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Quantum Biopharma EPS ResultsActual EPS-$1.41Consensus EPS -$0.37Beat/MissMissed by -$1.04One Year Ago EPSN/AQuantum Biopharma Revenue ResultsActual Revenue$2.09 millionExpected Revenue$2.09 millionBeat/MissBeat by +$2.00 thousandYoY Revenue GrowthN/AQuantum Biopharma Announcement DetailsQuarterQ1 2025Date5/14/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsQuantum Biopharma's next earnings date is estimated for Thursday, August 6, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Quantum Biopharma Earnings HeadlinesCritical Review: Quantum Biopharma (NASDAQ:QNTM) versus Imunon (NASDAQ:IMNN)July 3, 2026 | americanbankingnews.comQuantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive PodcastJuly 2, 2026 | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging StudyJune 29, 2026 | finance.yahoo.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging StudyJune 29, 2026 | markets.businessinsider.comNetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple SclerosisJune 26, 2026 | globenewswire.comSee More Quantum Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quantum Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quantum Biopharma and other key companies, straight to your email. Email Address About Quantum BiopharmaQuantum Biopharma (NASDAQ:QNTM) is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.View Quantum Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term InvestorsMarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponVisa’s Open USD Push Puts Circle’s Stablecoin Moat Under PressureGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
